Show simple item record

dc.contributor.authorWard, Jeanine
dc.contributor.authorKanchagar, Chitra
dc.contributor.authorVeksler-Lublinsky, Isana
dc.contributor.authorLee, Rosalind C.
dc.contributor.authorMcGill, Mitchell R.
dc.contributor.authorJaeschke, Hartmut
dc.contributor.authorCurry, Steven C.
dc.contributor.authorAmbros, Victor R.
dc.date2022-08-11T08:10:18.000
dc.date.accessioned2022-08-23T17:03:26Z
dc.date.available2022-08-23T17:03:26Z
dc.date.issued2014-08-19
dc.date.submitted2015-01-12
dc.identifier.citationProc Natl Acad Sci U S A. 2014 Aug 19;111(33):12169-74. doi: 10.1073/pnas.1412608111. Epub 2014 Aug 4. <a href="http://dx.doi.org/10.1073/pnas.1412608111">Link to article on publisher's site</a>
dc.identifier.issn0027-8424 (Linking)
dc.identifier.doi10.1073/pnas.1412608111
dc.identifier.pmid25092309
dc.identifier.urihttp://hdl.handle.net/20.500.14038/44425
dc.description.abstractWe have identified, by quantitative real-time PCR, hundreds of miRNAs that are dramatically elevated in the plasma or serum of acetaminophen (APAP) overdose patients. Most of these circulating microRNAs decrease toward normal levels during treatment with N-acetyl cysteine (NAC). We identified a set of 11 miRNAs whose profiles and dynamics in the circulation during NAC treatment can discriminate APAP hepatotoxicity from ischemic hepatitis. The elevation of certain miRNAs can precede the dramatic rise in the standard biomarker, alanine aminotransferase (ALT), and these miRNAs also respond more rapidly than ALT to successful treatment. Our results suggest that miRNAs can serve as sensitive diagnostic and prognostic clinical tools for severe liver injury and could be useful for monitoring drug-induced liver injury during drug discovery.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=25092309&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4143020/
dc.subjectAcetaminophen
dc.subjectAcetylcysteine
dc.subjectAlanine Transaminase
dc.subjectHepatitis
dc.subjectHumans
dc.subjectIschemia
dc.subjectMicroRNAs
dc.subjectPoisoning
dc.subjectReal-Time Polymerase Chain Reaction
dc.subjectBiochemistry
dc.subjectDigestive System Diseases
dc.subjectHepatology
dc.subjectMolecular Biology
dc.subjectMolecular Genetics
dc.titleCirculating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis
dc.typeJournal Article
dc.source.journaltitleProceedings of the National Academy of Sciences of the United States of America
dc.source.volume111
dc.source.issue33
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/pmm_pp/18
dc.identifier.contextkey6519769
html.description.abstract<p>We have identified, by quantitative real-time PCR, hundreds of miRNAs that are dramatically elevated in the plasma or serum of acetaminophen (APAP) overdose patients. Most of these circulating microRNAs decrease toward normal levels during treatment with N-acetyl cysteine (NAC). We identified a set of 11 miRNAs whose profiles and dynamics in the circulation during NAC treatment can discriminate APAP hepatotoxicity from ischemic hepatitis. The elevation of certain miRNAs can precede the dramatic rise in the standard biomarker, alanine aminotransferase (ALT), and these miRNAs also respond more rapidly than ALT to successful treatment. Our results suggest that miRNAs can serve as sensitive diagnostic and prognostic clinical tools for severe liver injury and could be useful for monitoring drug-induced liver injury during drug discovery.</p>
dc.identifier.submissionpathpmm_pp/18
dc.contributor.departmentDepartment of Medicine
dc.contributor.departmentRNA Therapeutics Institute
dc.contributor.departmentProgram in Molecular Medicine
dc.source.pages12169-74


This item appears in the following Collection(s)

Show simple item record